Hellmann MD, Ott PA, Zugazagoitia J, et al. Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032. J Clin Oncol. 35, 2017 (suppl; abstr 8503).
Camrelizumab plus rivoceranib versus sorafenib als eerstelijnsbehandeling bij inoperabel HCC
nov 2023 | Hepatologie, Immuuntherapie, Maag-darm-leveroncologie